Combinatorial approach to develop novel pre-therapeutic agents targeting virulence factors essential to clinically relevant pathogens
开发针对临床相关病原体必需毒力因子的新型治疗前药物的组合方法
基本信息
- 批准号:10681469
- 负责人:
- 金额:$ 24.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-08-09 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:Active SitesAffinityAntibiotic ResistanceAntibiotic TherapyAntibioticsAspartateBacteriaBindingBinding ProteinsBiochemicalBiologicalBiological AssayBiologyC-terminalCalorimetryCause of DeathCell DeathCell membraneCellsCessation of lifeChemicalsCollaborationsCommunicable DiseasesComputer AssistedConsumptionDataDevelopmentDrug resistanceESKAPE pathogensEnzyme ActivationFluorescent ProbesFoundationsFutureGoalsGram-Negative BacteriaHealthHealth Care CostsHost Defense MechanismHybridsInfectionInflammationKnowledgeLearningLegal patentLibrariesMedicineMembraneMentorsMethodsMicrobeMolecular TargetMusN-substituted GlycinesNatural ProductsNosocomial InfectionsOutcomePathogenesisPathogenicityPathologyPeptidesPeptoidsPeriodicityPharmaceutical ChemistryPharmaceutical PreparationsPhasePhenotypePhospholipase A2ProcessProductivityProteinsPseudomembranous ColitisPseudomonasPseudomonas aeruginosaRegulationResearchResistanceResolutionSeriesSerineSerine HydrolaseSpecificityStructureStructure-Activity RelationshipTechniquesTherapeuticTimeTitrationsType III Secretion System PathwayUnited StatesVirulenceVirulence FactorsVirulentWorkX-Ray Crystallographyacute infectionalgorithm developmentantibiotic resistant infectionsantimicrobialantimicrobial drugappendageclinically relevantcofactorcombatcombinatorialcommensal microbescostcost effectivedesigndrug candidatedrug discoveryextracellulargenetic approachglobal healthhealthcare-associated infectionshigh throughput screeninginhibitorinnovationinsightlead optimizationmacromoleculemarinemicrobialmicrobiomemicrobiotamultidrug-resistant Pseudomonas aeruginosamutantnovelnovel strategiesnovel therapeuticspathogenpathogenic bacteriapressurepreventpriority pathogenscreeningskillssmall moleculetargeted treatmenttherapeutic targettraitvirtual screening
项目摘要
Project Summary/Abstract
Antibiotic resistance is a serious global health threat. Current antibiotics target essential bacterial processes
and impose strong selective pressure for resistance. Upon antibiotic treatment, the healthy microbiota are
reduced in both number and diversity, leading to serious health consequences such as Clostridium difficile
colitis. Moreover, resistant traits can be transferred to other microbes, leading to the spread of antibiotic
resistance. Using virulence blockers to target specific pathogenicity mechanisms, while leaving the microbiota
intact, is a promising strategy to reduce resistance. This proposal will identify molecular target of a newly
discovered the type III secretion system (T3SS) inhibitor, and explore their modes of action for further
optimization and development. I will assess structure – activity relationship to optimize the T3SS inhibitors,
cyclic pepeptomers, and use affinity based method to identify their molecular targets in Pseudomonas
aeruginosa. Besides, target-based drug discovery offers the advantage of being low cost and less time
consuming. With the availability of high-resolution structure and development of algorithms to predict binding
affinity and poses of small molecules to its protein target, virtual screening can provide lead for optimization.
ExoU, an effector with phospholipase A2 activity, is the major effector in P. aeruginosa, one of six ESKAPE
pathogens which cause the majority of nosocomial infections in the U.S. and “escape” antimicrobial drugs.
ExoU has a serine/aspartate catalytic dyad and a separate cofactor-binding domain required for activation of
the enzyme. ExoU is highly toxic, associated with acute infection, antibiotic resistance and severe outcome in
patents. Delay ExoU expression can increase mice survival. Thus we set out to find ExoU inhibitors as a
strategy to treat acute infection and reduce resistance. We will identify ExoU inhibitors that 1) inhibit enzymatic
activity by targeting its catalytic residue serine, or 2) bind to the membrane localization domain which will
prevent ExoU's activation by virtual screening. The inhibitors that show binding affinity to ExoU in isothermal
titration calorimetry assay, and prevent cell death caused by ExoU will be chosen for optimization. Structure of
inhibitor-bound proteins will be solved using X-ray crystallography. I believe that my team of mentors (Drs.
Stone and Ottemann), advisors (Dr. Rubin, expert in X-ray crystallography; Dr. Jacobson, expert in computer-
aided drug discovery) and collaborators (Dr. Lokey, an expert in macromolecule synthesis, Drs. Crews and
Linington, natural product chemists) will provide me support to successfully carry out this project. With the
biochemical techniques I will learn, the structures and new inhibitors I will obtain in the K99 phase, I will then
collaborate with Dr. Shaw (medicinal chemist) and Dr. Jacobson to optimize the candidate hits in my
independent phase. This project extends my skill set in biochemical methods and has the potential to provide
substantial momentum towards drug discovery, and development. These will serve as the foundation of a R01
proposal to be prepared upon the completion of the main stages of this research plan.
项目概要/摘要
抗生素耐药性是一个严重的全球健康威胁。目前的抗生素针对重要的细菌过程
并对抵抗施加强大的选择压力。经过抗生素治疗后,健康的微生物群
数量和多样性均减少,导致严重的健康后果,例如艰难梭菌
结肠炎。此外,耐药性特征可以转移到其他微生物,导致抗生素的传播
反抗。使用毒力阻断剂针对特定的致病机制,同时保留微生物群
完好无损,是减少阻力的一个有前途的策略。该提案将确定新的分子靶标
发现了III型分泌系统(T3SS)抑制剂,并进一步探索其作用方式
优化和发展。我将评估结构-活性关系以优化 T3SS 抑制剂,
环状肽异构体,并使用基于亲和力的方法来鉴定其在假单胞菌中的分子靶标
铜绿假单胞菌。此外,基于靶标的药物发现具有成本低、时间短的优势
消耗。随着高分辨率结构的可用性和预测结合算法的开发
小分子与其蛋白质靶点的亲和力和姿势,虚拟筛选可以为优化提供线索。
ExoU 是一种具有磷脂酶 A2 活性的效应子,是铜绿假单胞菌(六种 ESKAPE 之一)的主要效应子
引起美国大多数医院感染的病原体并“逃避”抗菌药物。
ExoU 具有丝氨酸/天冬氨酸催化二元体和激活
酶。 ExoU 具有剧毒,与急性感染、抗生素耐药性和严重后果有关
专利。延迟 ExoU 表达可以增加小鼠的存活率。因此我们开始寻找 ExoU 抑制剂作为
治疗急性感染和降低抵抗力的策略。我们将鉴定 ExoU 抑制剂,1) 抑制酶
通过靶向其催化残基丝氨酸来提高活性,或 2) 与膜定位结构域结合,这将
通过虚拟筛选阻止ExoU的激活。在等温条件下显示出与 ExoU 结合亲和力的抑制剂
选择滴定量热法进行优化,防止ExoU引起的细胞死亡。结构
抑制剂结合蛋白将使用 X 射线晶体学来解析。我相信我的导师团队(Drs.
Stone 和 Ottemann),顾问(Rubin 博士,X 射线晶体学专家;Jacobson 博士,计算机专家)
辅助药物发现)和合作者(大分子合成专家 Lokey 博士、Crews 博士和
Linington,天然产物化学家)将为我成功开展这个项目提供支持。随着
我将学习的生化技术,我将在K99阶段获得的结构和新的抑制剂,然后我将
与 Shaw 博士(药物化学家)和 Jacobson 博士合作,优化我的候选命中
独立相。该项目扩展了我在生化方法方面的技能,并有可能提供
药物发现和开发的巨大动力。这些将作为 R01 的基础
提案将在本研究计划的主要阶段完成后准备。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hanh Ngoc Lam其他文献
Hanh Ngoc Lam的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hanh Ngoc Lam', 18)}}的其他基金
Combinatorial approach to develop novel pre-therapeutic agents targeting virulence factors essential to clinically relevant pathogens
开发针对临床相关病原体必需毒力因子的新型治疗前药物的组合方法
- 批准号:
10424305 - 财政年份:2021
- 资助金额:
$ 24.07万 - 项目类别:
Combinatorial approach to develop novel pre-therapeutic agents targeting virulence factors essential to clinically relevant pathogens
开发针对临床相关病原体必需毒力因子的新型治疗前药物的组合方法
- 批准号:
10659294 - 财政年份:2019
- 资助金额:
$ 24.07万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 24.07万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 24.07万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 24.07万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 24.07万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 24.07万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 24.07万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 24.07万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 24.07万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 24.07万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 24.07万 - 项目类别:
Continuing Grant